CTLA4 and cancer: Checkpoint inhibitors mainly targeting PD1/PDL1 and CTLA4 and personalized cancer vaccines (Gubin et al., 2014; Ott et al., 2017; Sahin et al., 2017) have been and still are heavily investigated in clinical trials.